Cargando…
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya
BACKGOUND: Sulphadoxine/sulphalene-pyrimethamine (SP) was adopted in Kenya as first line therapeutic for uncomplicated malaria in 1998. By the second half of 2003, there was convincing evidence that SP was failing and had to be replaced. Despite several descriptive investigations of policy change an...
Autores principales: | Amin, Abdinasir A, Zurovac, Dejan, Kangwana, Beth B, Greenfield, Joanne, Otieno, Dorothy N, Akhwale, Willis S, Snow, Robert W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892027/ https://www.ncbi.nlm.nih.gov/pubmed/17535417 http://dx.doi.org/10.1186/1475-2875-6-72 |
Ejemplares similares
-
Major Improvements in the Quality of Malaria Case-Management under the “Test and Treat” Policy in Kenya
por: Zurovac, Dejan, et al.
Publicado: (2014) -
Malaria Case-Management following Change of Policy to Universal Parasitological Diagnosis and Targeted Artemisinin-Based Combination Therapy in Kenya
por: Nyandigisi, Andrew, et al.
Publicado: (2011) -
Evaluating Different Dimensions of Programme Effectiveness for Private Medicine Retailer Malaria Control Interventions in Kenya
por: Abuya, Timothy O., et al.
Publicado: (2010) -
Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets
por: Chuma, Jane, et al.
Publicado: (2009) -
Translation of artemether–lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya
por: Zurovac, D, et al.
Publicado: (2008)